Dose-Dense Chemotherapy Regimen for Breast Cancer Associated with Significant Decline in Ovarian Reserve

被引：0

作者：

Chamani, Isaac J. ^{[1
,4
]}

Gannon, Alexandra ^{[1
]}

Connell, Phillip T. ^{[1
]}

Bisen, Ajit ^{[3
]}

Kovanci, Ertug ^{[2
]}

Sangi-Haghpeykar, Haleh ^{[1
]}

Woodard, Terri ^{[1
,3
]}

McKenzie, Laurie J. ^{[1
,3
]}

机构：

[1] Baylor Coll Med, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Houston, TX USA

[2] HART Fertil Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX USA

[4] Baylor Coll Med, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, 6651 Main St,Suite 1020, Houston, TX 77030 USA

来源：

JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY | 2024年 / 13卷 / 03期

关键词：

breast cancer; dose-dense chemotherapy; ovarian function; AMH; ANTI-MULLERIAN HORMONE; ANTIMULLERIAN HORMONE; PREMENOPAUSAL WOMEN; AGE; 40; AMENORRHEA;

D O I：

10.1089/jayao.2023.0079

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: To determine the impact of dose-dense chemotherapy administration on ovarian reserve in women undergoing treatment for breast cancer.Patients and Methods: We conducted a retrospective cohort study of reproductive age women who underwent dose-dense chemotherapy regimens with doxorubicin hydrochloride and cyclophosphamide with or without paclitaxel for a new diagnosis of breast cancer. We compared pre- and post-treatment serum antimullerian hormone (AMH) levels and assessed changes in AMH over time.Results: Fifty-seven patients met inclusion criteria. Median pre-treatment AMH was 2.9 ng/mL, whereas post-treatment AMH was 0.1 ng/mL, demonstrating a dramatic reduction in AMH levels after treatment with a dose-dense regimen. This change was independent of age and was sustained over 12 months from treatment completion.Conclusions: Dose-dense chemotherapy regimens for breast cancer lead to marked and sustained decreases in AMH irrespective of patient age.

引用

页码：465 / 468

页数：4

共 50 条

[41] Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials [J].

Fausto Petrelli ;

Mary Cabiddu ;

Andrea Coinu ;

Karen Borgonovo ;

Mara Ghilardi ;

Veronica Lonati ;

Sandro Barni .

Breast Cancer Research and Treatment, 2015, 151 :251-259

[42] Changes in Markers of Ovarian Reserve and Endocrine Function in Young Women With Breast Cancer Undergoing Adjuvant Chemotherapy [J].

Yu, Bo ;

Douglas, Nataki ;

Ferin, Michel J. ;

Nakhuda, Gary S. ;

Crew, Katherine ;

Lobo, Rogerio A. ;

Hershman, Dawn L. .

CANCER, 2010, 116 (09) :2099-2105

[43] Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials [J].

Petrelli, Fausto ;

Cabiddu, Mary ;

Coinu, Andrea ;

Borgonovo, Karen ;

Ghilardi, Mara ;

Lonati, Veronica ;

Barni, Sandro .

BREAST CANCER RESEARCH AND TREATMENT, 2015, 151 (02) :251-259

[44] Neoadjuvant dose-dense chemotherapy for locally advanced breast cancer: a meta-analysis of published studies [J].

Petrelli, Fausto ;

Coinu, Andrea ;

Lonati, Veronica ;

Cabiddu, Mary ;

Ghilardi, Mara ;

Borgonovo, Karen ;

Barni, Sandro .

ANTI-CANCER DRUGS, 2016, 27 (07) :702-708

[45] Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer [J].

Lyman, Gary H. ;

Barron, Richard L. ;

Natoli, Jaime L. ;

Miller, Ross M. .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 81 (03) :296-308

[46] Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer [J].

Fountzilas, G ;

Papadimitriou, C ;

Aravantinos, G ;

Nicolaides, C ;

Stathopoulos, G ;

Bafaloukos, D ;

Kalofonos, H ;

Ekonomopoulos, T ;

Skarlos, D ;

Pavlidis, N ;

Dimopoulos, AM .

ONCOLOGY, 2001, 60 (03) :214-220

[47] Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies [J].

Lambertini, Matteo ;

Ceppi, Marcello ;

Cognetti, Francesco ;

Cavazzini, Giovanna ;

De Laurentiis, Michele ;

De Placido, Sabino ;

Michelotti, Andrea ;

Bisagni, Giancarlo ;

Durando, Antonio ;

Valle, Enrichetta ;

Scotto, Tiziana ;

De Censi, Andrea ;

Turletti, Anna ;

Benasso, Marco ;

Barni, Sandro ;

Montemurro, Filippo ;

Puglisi, Fabio ;

Levaggi, Alessia ;

Giraudi, Sara ;

Bighin, Claudia ;

Bruzzi, Paolo ;

Del Mastro, Lucia .

EUROPEAN JOURNAL OF CANCER, 2017, 71 :34-42

[48] Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial [J].

Matikas, Alexios ;

Papakonstantinou, Andri ;

Loibl, Sibylle ;

Steger, Guenther G. ;

Untch, Michael ;

Johansson, Hemming ;

Tsiknakis, Nikos ;

Hellstrom, Mats ;

Greil, Richard ;

Moebus, Volker ;

Gnant, Michael ;

Bergh, Jonas ;

Foukakis, Theodoros .

LANCET REGIONAL HEALTH-EUROPE, 2025, 49

[49] Anemia requiring transfusion in breast cancer patients on dose-dense chemotherapy: Prevalence, risk factors, cost and effect on disease outcome [J].

Sharma, Parth ;

Georgy, Josh Thomas ;

Andrews, Anand George ;

John, Ajoy Oommen ;

Joel, Anjana ;

Chacko, Raju Titus ;

Premkumar, Prasanna Samuel ;

Singh, Ashish .

SUPPORTIVE CARE IN CANCER, 2022, 30 (06) :5519-5526

[50] Effect of peg-filgrastim-supported dose-dense adjuvant chemotherapy on the peripheral blood leukocyte phenotype in breast cancer patients [J].

Collova, Elena ;

Rovati, Bianca ;

Grasso, Donatella ;

Bencardino, Katia ;

Manzoni, Mariangela ;

Danova, Marco .

MOLECULAR MEDICINE REPORTS, 2009, 2 (01) :85-88

← 1 2 3 4 5 →